Detailed data on AstraZeneca-Oxford Covid-19 vaccine show it has moderate efficacy
The Covid-19 vaccine being developed by the University of Oxford and AstraZeneca appears to have moderate efficacy in preventing symptomatic illness, and may significantly reduce hospitalization from the disease, data from four clinical trials of the vaccine reveal.
Topline data on the vaccine from a Phase 3 trial were released in November. The new data, published Tuesday in The Lancet, draw from trials in various phases and include safety data on more than 20,000 participants.
